245 related articles for article (PubMed ID: 28384639)
1. Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients.
Dereure O; Missan H; Girard C; Costes V; Guillot B
Dermatology; 2016; 232(6):721-730. PubMed ID: 28384639
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature.
Jarkowski A; Hare R; Loud P; Skitzki JJ; Kane JM; May KS; Zeitouni NC; Nestico J; Vona KL; Groman A; Khushalani NI
Am J Clin Oncol; 2016 Dec; 39(6):545-548. PubMed ID: 24879468
[TBL] [Abstract][Full Text] [Related]
3. Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.
Picard A; Pedeutour F; Peyrade F; Saudes L; Duranton-Tanneur V; Chamorey E; Cardot-Leccia N; Sudaka A; Ettaiche M; Benchetrit M; Poissonnet G; Weinbreck N; Dadone B; Lacour JP; Passeron T; Montaudié H
JAMA Dermatol; 2017 Apr; 153(4):291-298. PubMed ID: 28259104
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of cetuximab in the treatment of squamous cell carcinoma.
Preneau S; Rio E; Brocard A; Peuvrel L; Nguyen JM; Quéreux G; Dreno B
J Dermatolog Treat; 2014 Oct; 25(5):424-7. PubMed ID: 23167307
[TBL] [Abstract][Full Text] [Related]
5. Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.
Chapalain M; Baroudjian B; Dupont A; Lhote R; Lambert J; Bagot M; Lebbe C; Basset-Seguin N
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1202-1209. PubMed ID: 31587382
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma.
Joseph K; Alkaabi K; Warkentin H; Ghosh S; Jha N; Smylie M; Walker J
J Med Imaging Radiat Oncol; 2019 Apr; 63(2):257-263. PubMed ID: 30549229
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Maubec E; Petrow P; Scheer-Senyarich I; Duvillard P; Lacroix L; Gelly J; Certain A; Duval X; Crickx B; Buffard V; Basset-Seguin N; Saez P; Duval-Modeste AB; Adamski H; Mansard S; Grange F; Dompmartin A; Faivre S; Mentré F; Avril MF
J Clin Oncol; 2011 Sep; 29(25):3419-26. PubMed ID: 21810686
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas.
Reigneau M; Robert C; Routier E; Mamelle G; Moya-Plana A; Tomasic G; Mateus C
Br J Dermatol; 2015 Aug; 173(2):527-34. PubMed ID: 25704233
[TBL] [Abstract][Full Text] [Related]
13. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma.
O'Bryan K; Sherman W; Niedt GW; Taback B; Manolidis S; Wang A; Ratner D
J Am Acad Dermatol; 2013 Oct; 69(4):595-602.e1. PubMed ID: 23871719
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
16. Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.
Pellini Ferreira B; Redman M; Baker KK; Martins R; Eaton KD; Chow LQM; Baik CS; Goulart B; Lee SM; Santana-Davila R; Rodriguez CP
Laryngoscope; 2017 Jul; 127(7):1583-1588. PubMed ID: 27905113
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center.
Trodello C; Higgins S; Ahadiat O; Ragab O; In G; Hawkins M; Wysong A
Dermatol Surg; 2019 Feb; 45(2):254-267. PubMed ID: 30672860
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study.
Lonardi S; Prete AA; Morano F; Messina M; Formica V; Corsi DC; Orciuolo C; Frassineti GL; Zampino MG; Casagrande M; Masi G; Ronzoni M; Scartozzi M; Buonadonna A; Mosconi S; Ratti M; Sartore-Bianchi A; Tamburini E; Prisciandaro M; Bergamo F; Spada M; Corallo S; Vettore V; Loupakis F; Fassan M; Del Bianco P; Zagonel V; Pietrantonio F
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815354
[TBL] [Abstract][Full Text] [Related]
19. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel.
Mecca C; Ponzetti A; Caliendo V; Ciuffreda L; Lista P
Eur J Dermatol; 2012; 22(6):758-61. PubMed ID: 23131415
[TBL] [Abstract][Full Text] [Related]
20. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
